‘India must push for tariff relief to sustain pharma leadership‘

Commenting on the trade disruptions between US and India, CK Govil, CMD, Activair Airfreight, said, “Tariffs continue to weigh heavily on India’s pharma exports, driving up costs and undermining competitiveness in key markets such as the US. As global trade dynamics shift and tensions between the US and India persist over pricing and market access, Indian pharma exporters face mounting uncertainty. While India continues to be leading supplier of affordable generics to the world, higher tariffs and regulatory hurdles in importing countries threaten supply chain stability and restrict patient access to essential medicines. To safeguard its leadership in global healthcare, India must engage in trade negotiations, seek tariff relief, and strengthen partnerships to ensure open, reliable, and resilient market access.”